2269 — WuXi Biologics (Cayman) Share News
0.000.00%
Last trade - 00:00- HK$198.43bn
- HK$193.91bn
- CNY21.79bn
Brief: Blackrock's Long Position In Wuxi Biologics (Cayman) Increases To 6.14% On Jan 2, HKEX Shows
Brief: Blackrock Inc's Long Position In Wuxi Biologics Increases To 5.43% On Oct 10, HKEX Filing Shows
Brief: HKEX Says Blackrock's Long Position In Wuxi Biologics (Cayman) Decreases To 4.99%
Hansoh leads slide in HK-listed biotech shares on report of US curbs
Brief: WuXi Biologics Launches Green CRDMO White Paper To Advance Sustainability In Biologics Industry
WuXi XDC stock peaks on share sales for service expansion
WuXi Biologics rises most in 3 weeks on robust first-half results
Brief: Wuxi Biologics Posts H1 Net Income RMB 2,756.6 Million
WuXi Biologics touches 1-1/2-year high on robust earnings forecast
Brief: Wuxi Biologics (Cayman) Says Revenue Expected To Increase 16%, Profit Up 54% For HY
Brief: Wuxi Biologics Secures FDA Pli Approval For Five Facilities, First For Commercial Pfs Line
Focus: China pharma projects disrupted by Sino-US tensions
WuXi Biologics drops most in 2 months as key shareholder cuts stake
Brief: Wuxi Biologics Announces Placing Of Existing Shares By Substantial Shareholder
Brief: Wuxi Biologics Appoints Sherry Xuejun Gu As An Executive Director
WuXi Biologics rises on Terumo's drug product plant deal in Germany
Brief: Terumo Says It And Wuxi Biologics Enter Into Agreement On A Drug Product Plant In Leverkusen, Germany
Brief: WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
Brief: WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln